GLP-1 receptor agonists reduced apnea-hypopnea index by 13.89 events per hour while triggering 12.46 kg weight loss in obstructive sleep apnea patients across four randomized controlled trials. The medications also lowered systolic blood pressure by 4.86 mmHg and reduced diastolic pressure significantly. This represents a paradigm shift in sleep apnea treatment beyond traditional CPAP therapy. The dual mechanism—direct respiratory improvement plus weight reduction—addresses OSA's root cause rather than just managing symptoms. For the estimated 936 million adults worldwide with sleep apnea, this offers hope for a pharmaceutical intervention that tackles multiple health risks simultaneously. The cardiovascular benefits are particularly compelling given OSA's strong association with heart disease and stroke. However, these results come from just four trials, limiting long-term safety and durability data. The weight loss component aligns with GLP-1 drugs' established obesity benefits, but the direct respiratory effects suggest previously unknown mechanisms. While promising, real-world application will depend on insurance coverage, long-term adherence, and identifying which OSA patients benefit most from this expensive but potentially transformative intervention.